IDNA · ARCA · ETF
iShares Genomics Immunology and Healthcare ETF (IDNA) Price, Holdings & Fees
iShares Genomics Immunology and Healthcare ETF (IDNA) closed at $351.36 on Oct 9, 2026, up 0.53% from the previous close of $349.52.
Share price, past year
1Y +27.11%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $351.36 |
| Sep 30, 2026 | $349.55 |
| Aug 31, 2026 | $335.32 |
| Jul 31, 2026 | $321.67 |
| Jun 30, 2026 | $314.13 |
| May 29, 2026 | $311.62 |
| Apr 30, 2026 | $319.38 |
| Mar 31, 2026 | $318.48 |
| Feb 27, 2026 | $301.22 |
| Jan 30, 2026 | $311.33 |
| Dec 31, 2025 | $291.07 |
| Nov 28, 2025 | $287.45 |
| Oct 31, 2025 | $281.90 |
Key statistics
- Expense ratio
- 0.47%
- as of Jul 31, 2025
- Net assets
- $190.9M
- as of Jul 31, 2026
- Holdings
- 61
- as of Jul 31, 2026
- 52-week range
- $276.43 – $358.61
iShares Genomics Immunology and Healthcare ETF's expense ratio is 0.47%: $47.00 a year on $10,000 invested.
Holdings
iShares Genomics Immunology and Healthcare ETF held 61 investments worth $190.86M as of Jul 31, 2026. Its largest holding was BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares, at 10.39% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 10.39% | $19.83M |
| 2 | Bayer Aktiengesellschaft | 4.81% | $9.18M |
| 3 | Twist Bioscience Corp | 4.79% | $9.15M |
| 4 | REVOLUTION MEDICINES, INC. | 4.55% | $8.69M |
| 5 | REGENERON PHARMACEUTICALS, INC. | 4.35% | $8.30M |
| 6 | GENMAB A/S | 4.23% | $8.08M |
| 7 | INCYTE CORPORATION | 4.23% | $8.08M |
| 8 | MODERNA, INC. | 4.19% | $7.99M |
| 9 | Takeda Pharmaceutical Company Limited | 4.05% | $7.73M |
| 10 | MERCK & CO., INC. | 3.91% | $7.46M |
| 11 | VERTEX PHARMACEUTICALS INCORPORATED | 3.87% | $7.39M |
| 12 | Roche Holding AG | 3.85% | $7.34M |
| 13 | IPSEN SA | 3.84% | $7.33M |
| 14 | BioNTech SE | 3.73% | $7.11M |
| 15 | EXELIXIS, INC. | 3.65% | $6.96M |
| 16 | GSK PLC | 3.63% | $6.93M |
| 17 | SANOFI SA | 3.46% | $6.61M |
| 18 | IDEAYA Biosciences Inc | 3.36% | $6.41M |
| 19 | Immunitybio Inc | 3.07% | $5.86M |
| 20 | ARCUS BIOSCIENCES, INC. | 2.68% | $5.12M |
| 21 | CARIS LIFE SCIENCES, INC. | 2.18% | $4.17M |
| 22 | ONO PHARMACEUTICAL CO., LTD. | 1.91% | $3.65M |
| 23 | Iovance Biotherapeutics Inc | 1.80% | $3.43M |
| 24 | NUVATION BIO INC. | 1.78% | $3.39M |
| 25 | CRISPR Therapeutics AG | 1.57% | $2.99M |
Top 25 of 61 holdings, as of Jul 31, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 96.02% |
| Cash and short-term investments | 10.49% |
| Other | 3.81% |
| Derivatives | 0.01% |
| Country | % of fund |
|---|---|
| United States | 70.15% |
| Germany | 8.54% |
| France | 7.76% |
| Japan | 6.00% |
| Switzerland | 5.41% |
| Denmark | 4.24% |
| United Kingdom | 3.66% |
| China | 2.26% |
| Canada | 1.52% |
| Luxembourg | 0.53% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jul 31, 2026, iShares Genomics Immunology and Healthcare ETF's total return was +10.33%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jul 31, 2026 | −3.90% |
| Jun 30, 2026 | +12.93% |
| May 31, 2026 | +1.66% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- iShares Genomics Immunology and Healthcare ETF
- Ticker
- IDNA
- Exchange
- ARCA
- Fund type
- ETF
- Trust
- iSHARES TRUST
- SEC series ID
- S000065599
- SEC CIK
- 0001100663
- Fractional shares
- Yes
Recent SEC filings
- Sep 23, 2026
- Oct 5, 2026
- 485BPOSProspectus updateSep 14, 2026
- 485BPOSProspectus updateAug 21, 2026
- 485BPOSProspectus updateJul 27, 2026
- 485BPOSProspectus updateJul 7, 2026
- Jul 2, 2026
- Jul 2, 2026
Shareholder reports and prospectuses are filed by iSHARES TRUST, the trust behind iShares Genomics Immunology and Healthcare ETF, and cover all of its funds.
Frequently asked questions
What is IDNA's price?
iShares Genomics Immunology and Healthcare ETF (IDNA) closed at $351.36 on Oct 9, 2026, up 0.53% from the previous close of $349.52.
What is IDNA's expense ratio?
iShares Genomics Immunology and Healthcare ETF's expense ratio is 0.47%: $47.00 a year on $10,000 invested.
What does IDNA hold?
iShares Genomics Immunology and Healthcare ETF held 61 investments worth $190.86M as of Jul 31, 2026. Its largest holding was BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares, at 10.39% of the fund. Its five largest holdings were BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares, Bayer Aktiengesellschaft, Twist Bioscience Corp, REVOLUTION MEDICINES, INC., REGENERON PHARMACEUTICALS, INC..
How has IDNA performed?
Over the 3 months to Jul 31, 2026, iShares Genomics Immunology and Healthcare ETF's total return was +10.33%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jul 31, 2026 (filed Sep 23, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jul 31, 2025. Prices are generated sample data for development. Data sources and disclosures